Holen Sie sich die Stockscreener-App
15.55
3.67%
0.55
Handel nachbörslich:
15.40
-0.15
-0.96%
Schlusskurs vom Vortag:
$15.00
Offen:
$15.58
24-Stunden-Volumen:
70,453
Relative Volume:
3.37
Marktkapitalisierung:
$176.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+19.62%
1M Leistung:
+5.57%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$14.84
$15.89
1-Wochen-Bereich:
$12.60
$15.90
52-Wochen-Spanne:
$11.17
$15.90
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Firmenname
Palvella Therapeutics Inc
Sektor
Branche
Telefon
857-246-8998
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie PVLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
15.55 | 176.51M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 120.86B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 77.62B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.62B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-05 | Eingeleitet | TD Cowen | Buy |
| 2024-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-03-19 | Eingeleitet | Evercore ISI | Outperform |
| 2018-03-19 | Eingeleitet | Jefferies | Buy |
| 2018-01-16 | Bestätigt | H.C. Wainwright | Buy |
| 2017-05-30 | Eingeleitet | Rodman & Renshaw | Buy |
| 2016-08-05 | Fortgesetzt | ROTH Capital | Buy |
| 2015-08-12 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Palvella Therapeutics Inc Aktie (PVLA) Neueste Nachrichten
Mineralys Therapeutics to Announce Q4 and Full-Year 2024 Financial Results - MyChesCo
This Intuitive Machines Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
TD Cowen Initiates Palvella Therapeutics at Buy With $44 Price Target -February 05, 2025 at 07:50 am EST - Marketscreener.com
TD Cowen Initiates Coverage on Palvella Therapeutics (NASDAQ:PVLA) - MarketBeat
Cowen initiates Palvella Therapeutics with buy, $44 target By Investing.com - Investing.com UK
Palvella Therapeutics Kicks Off Phase 2 Trial for Promising Cutaneous VM Treatment - MSN
Research Analysts Issue Forecasts for PVLA FY2025 Earnings - Defense World
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease - MSN
Palvella Therapeutics’ (PVLA) Buy Rating Reiterated at HC Wainwright - Defense World
Palvella reports positive phase 2 study on QTORIN rapamycin for rare skin disease - Investing.com India
Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies - The Manila Times
Palvella Therapeutics Announces Publication of Results from - GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations - The Manila Times
Palvella Therapeutics Announces First Patients Dosed in - GlobeNewswire
Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN - The Bakersfield Californian
Brokers Issue Forecasts for PVLA FY2029 Earnings - Defense World
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MSN
Palvella Therapeutics (NASDAQ:PVLA) Given Buy Rating at HC Wainwright - Defense World
Palvella Therapeutics registers 5.6M shares by selling holders - MSN
Analysts Issue Forecasts for PVLA FY2024 Earnings - Defense World
What is HC Wainwright’s Estimate for PVLA Q4 Earnings? - Defense World
Palvella Therapeutics initiated with a Buy at H.C. Wainwright - Yahoo Finance
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at HC Wainwright - Defense World
Palvella Therapeutics stock gains attention with Phase 3 trial data expected in early 2026 - Investing.com Canada
Pieris Pharmaceuticals: Q1 Earnings Snapshot - Marketscreener.com
Wayne’s Palvella Therapeutics Completes Reverse Merger with Pieris Pharmaceutical - MSN
Palvella therapeutics director George Jenkins acquires $51,720 in shares By Investing.com - Investing.com Canada
Palvella therapeutics director George Jenkins acquires $51,720 in shares - Investing.com
Pieris Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2021 - Marketscreener.com
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific - Marketscreener.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 - Marketscreener.com
Palvella Therapeutics closes on Pieris merger; completes nearly $80M private placement - Pennsylvania Business Report
After losing AstraZeneca collab, Boston biotech opts for reverse merger - The Business Journals
Main Line biotech firm completes reverse merger, raises $78.9 million - The Business Journals
Palvella Therapeutics Closes Merger with Pieris Pharmaceuticals - citybiz
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Pieris Pharmaceuticals: Q3 Earnings Snapshot - Marketscreener.com
PIERIS PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pieris Pharmaceuticals, Inc.PIRS - Marketscreener.com
Pieris Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million - The Manila Times
Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent - The Bakersfield Californian
Palvella Therapeutics Announces Closing of Merger with - GlobeNewswire
Finanzdaten der Palvella Therapeutics Inc-Aktie (PVLA)
Es liegen keine Finanzdaten für Palvella Therapeutics Inc (PVLA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Palvella Therapeutics Inc-Aktie (PVLA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GERAGHTY JAMES A | Director |
Aug 07 '24 |
Buy |
1.00 |
1 |
1 |
1 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 12 '24 |
Buy |
15.88 |
3,000 |
47,647 |
129,574 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 09 '24 |
Buy |
14.89 |
3,000 |
44,679 |
127,331 |
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):